샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514158

세계의 불안장애 치료 시장

Anxiety Disorder Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 196 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 불안장애 치료 시장은 2030년까지 121억 달러에 달할 전망

2023년에 102억 달러로 평가된 세계의 불안장애 치료 시장은 2023년부터 2030년까지 CAGR 2.4%로 성장할 전망이며, 2030년에는 121억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 항우울제는 CAGR 3.0%로 성장을 지속하고, 분석 기간 종료 시 49억 달러에 달할 것으로 예측됩니다. 항불안제 부문의 성장률은 분석 기간 동안 CAGR 2.6%로 추정됩니다.

미국 시장은 28억 달러, 중국은 CAGR 4.3%로 성장할 것으로 예측

미국의 불안장애 치료 시장은 2023년 28억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 분석 기간 2023년부터 2030년까지 CAGR 4.3%로 전망되며, 2030년까지 24억 달러 규모에 이를 것으로 예측되고 있습니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.3%와 2.2%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 1.7%로 성장할 것으로 예측됩니다.

불안장애 치료-주요 동향 및 촉진요인

불안장애 치료에는 일반 불안장애(GAD), 공황 장애, 사교 불안장애, 특정 공포증 등 다양한 불안장애의 증상을 완화하도록 설계된 다양한 치료 접근법과 약물이 포함됩니다. 이러한 치료는 과도한 공포, 걱정 및 일상 기능에 큰 영향을 미치는 관련 행동의 변화를 줄이는 것을 목표로 합니다. 심리 치료, 특히 인지 행동 치료(CBT)는 불안장애의 최전선 치료법으로 간주됩니다. CBT는 환자가 부정적인 사고 패턴과 행동을 파악하고 수정하는 데 도움을 주며 불안을 관리하는 대처 전략을 가르칩니다. 다른 치료 접근법은 환자를 통제된 방식으로 점차적으로 두려움 상황에 노출시키는 노출 요법과, 환자가 행동을 바꾸는 것을 약속하면서 불안을 받아들이도록 촉구하는 수용 약정 요법(ACT) 등입니다.

약물 요법은 불안장애 치료의 또 다른 요인이며, 종종 심리 요법과 함께 사용됩니다. 선택적 세로토닌 재 흡수 억제제(SSRI)와 세로토닌 노르 에피네프린 재 흡수 억제제(SNRI)는 효능과 비교적 양호한 부작용 프로파일을 통해 제1선택 약물로 일반적으로 처방됩니다. 벤조디아제핀계 약물은 단기 완화에 효과적이지만, 종속 및 이탈 문제의 위험이 있기 때문에 일반적으로 신중하게 처방됩니다. 또한 불안의 신체 증상을 관리하는 데 일반적으로 사용되는 베타 차단제 및 치료 저항성 사례에 대한 비정형 항정신병 약물과 같은 다른 유형의 약물도 사용됩니다. 최근의 약물 요법의 동향은 환자에게 더 나은 결과를 제공하기 위해 부작용이 적고 글루탐산 및 엔도칸나비노이드 시스템을 표적으로하는 새로운 작용기전을 가진 약물의 개발에 초점을 맞추었습니다.

불안장애 치료 시장의 성장은 몇 가지 요인에 의해 발생합니다. 첫째, 세계적으로 불안장애의 유병률이 상승하고 있는 것이 중요한 촉진요인이며, 인지도 및 진단의 향상이 효과적인 치료에 대한 수요 증가에 기여하고 있습니다. 둘째, 디지털 건강의 기술적 진보는 원격 치료와 모바일 건강 애플리케이션을 통해 정신 건강 관리에 대한 액세스를 확대하고, 특히 원격 지역에서의 치료가 더 친숙해졌습니다. 셋째, 정신건강에 대한 편견이 점차 희미해지고, 보다 많은 사람이 치료를 받게 되고 있습니다. 게다가 약물 치료의 지속적인 연구개발은 효능과 안전성이 개선된 혁신적인 치료법을 만들어 냈습니다. 또한 기본 관리 설정에 정신 건강 서비스를 통합하면 불안장애를 식별하고 관리하는 기능이 향상되었습니다. 마지막으로, 정부의 호의적인 정책과 건강 관리 지출 증가는 정신 건강 치료의 개척과 접근성을 돕고 시장 성장을 더욱 촉진하고 있습니다. 이러한 요인은 종합적으로 불안장애 치료 시장의 역동적이고 발전적인 성질을 부각시키고 세계의 정신 건강 성과 개선에 중요한 역할을 강조합니다.

조사 대상 기업 예(총 63건)

  • Abbott Laboratories, Inc.
  • Allergan PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Noven Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Shionogi & Co., Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.07.24

Global Anxiety Disorder Treatment Market to Reach US$12.1 Billion by 2030

The global market for Anxiety Disorder Treatment estimated at US$10.2 Billion in the year 2023, is expected to reach US$12.1 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2023-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$4.9 Billion by the end of the analysis period. Growth in the Anxiolytics segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.8 Billion While China is Forecast to Grow at 4.3% CAGR

The Anxiety Disorder Treatment market in the U.S. is estimated at US$2.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 4.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Anxiety Disorder Treatment - Key Trends and Drivers

Anxiety disorder treatment encompasses a range of therapeutic approaches and medications designed to alleviate the symptoms of various anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and specific phobias. These treatments aim to reduce excessive fear, worry, and associated behavioral changes that significantly impact daily functioning. Psychotherapy, particularly cognitive-behavioral therapy (CBT), is considered a frontline treatment for anxiety disorders. CBT helps patients identify and modify negative thought patterns and behaviors, teaching coping strategies to manage anxiety. Other therapeutic approaches include exposure therapy, which gradually exposes patients to feared situations in a controlled manner, and acceptance and commitment therapy (ACT), which encourages patients to accept their anxiety while committing to behavior changes.

Medications are another cornerstone of anxiety disorder treatment, often used in conjunction with psychotherapy. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly prescribed first-line medications due to their efficacy and relatively favorable side effect profiles. Benzodiazepines, while effective for short-term relief, are generally prescribed with caution due to the risk of dependency and withdrawal issues. Additionally, other classes of medications such as beta-blockers, which are typically used to manage physical symptoms of anxiety, and atypical antipsychotics for treatment-resistant cases, are also utilized. Recent advancements in pharmacotherapy are focusing on developing medications with fewer side effects and novel mechanisms of action, such as targeting the glutamate system or the endocannabinoid system, to provide better outcomes for patients.

The growth in the anxiety disorder treatment market is driven by several factors. Firstly, the rising prevalence of anxiety disorders globally is a significant driver, with increasing awareness and diagnosis contributing to higher demand for effective treatments. Secondly, technological advancements in digital health are expanding access to mental health care through teletherapy and mobile health applications, making treatments more accessible, especially in remote areas. Thirdly, the stigma around mental health is gradually diminishing, encouraging more individuals to seek treatment. Moreover, continuous research and development in pharmacotherapy are leading to innovative treatment options with improved efficacy and safety profiles. Additionally, the integration of mental health services into primary care settings is improving the identification and management of anxiety disorders. Lastly, favorable government policies and increasing healthcare expenditure are supporting the development and accessibility of mental health treatments, further propelling market growth. These factors collectively highlight the dynamic and evolving nature of the anxiety disorder treatment market, emphasizing its critical role in improving mental health outcomes globally.

Select Competitors (Total 63 Featured) -

  • Abbott Laboratories, Inc.
  • Allergan PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Noven Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Shionogi & Co., Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Anxiety Disorder Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Anxiety Disorders Throws the Spotlight on Need for Effective Treatments
    • Adoption of Digital Therapeutics in Anxiety Management Spurs Market Expansion
    • Integration of Mental Health Services into Primary Care Strengthens Business Case for Comprehensive Care Models
    • Continuous Research and Development in Pharmacotherapy Generates New Treatment Options
    • Innovations in Psychotherapy Techniques Improves Patient Outcomes
    • Rising Utilization of Mobile Health Applications Drives Demand for Accessible Treatment Options
    • Development of Medications with Novel Mechanisms of Action Expands Therapeutic Landscape
    • Growing Popularity of Acceptance and Commitment Therapy (ACT) Generates Interest in Alternative Therapies
    • Advances in Understanding of Neurobiological Mechanisms Propel Growth in Personalized Medicine
    • Growing Investment in Mental Health Infrastructure Expands Addressable Market Opportunity
    • Rising Awareness of Comorbid Conditions Drives Comprehensive Treatment Strategies
    • Expansion of Insurance Coverage for Mental Health Services Strengthens Business Case for Providers
    • Growth in Corporate Mental Health Programs Generates Demand for Anxiety Disorder Treatments
    • Advances in Genetic Research Propel Growth in Targeted Anxiety Therapies
    • Increasing Consumer Preference for Non-Pharmacological Treatments Drives Adoption of Alternative Therapies
    • Challenges in Medication Side Effects Create Opportunities for New Drug Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anxiety Disorder Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Anxiety Disorder Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anxiolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anxiolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Anxiolytics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Noradrenergic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Noradrenergic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Noradrenergic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Atypical Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Atypical Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Atypical Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • JAPAN
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • CHINA
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • EUROPE
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Anxiety Disorder Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • FRANCE
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • GERMANY
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Anxiety Disorder Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • INDIA
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Anxiety Disorder Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Anxiety Disorder Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • AFRICA
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제